Literature DB >> 19952505

In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH).

Fumiaki Beppu, Yoshimi Niwano, Emiko Sato, Masahiro Kohno, Takayuki Tsukui, Masashi Hosokawa, Kazuo Miyashita.   

Abstract

Mutagenicity of fucoxanthinol (FXOH), the major compound after oral ingestion of fucoxanthin (FX), was evaluated by in vitro Ames test, and of FX by in vivo micronucleus test. In in vitro Ames test, bacterial reverse mutation was examined by using Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537, and Escherichia coli WP2uvrA/pKM101, with or without metabolic activation by S9 mix in the preincubation method, and mutagenicity of FXOH was found to be negative in all cases. In in vivo micronucleus test, mice were orally administered with FX at doses of 500, 1,000 and 2,000 mg/kg, and the bone marrow cells were taken 24 hr after the administration to observe the incidence of micronucleus cells, and mutagenicity of FX was found to be negative at all doses. Based on the data of the present study it can be presumed that orally administered FX is a safe compound in terms of mutagenicity under the experimental conditions employed here.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952505     DOI: 10.2131/jts.34.693

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  17 in total

1.  Health-Promoting Functions of the Marine Carotenoid Fucoxanthin.

Authors:  Masashi Hosokawa
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Antiproliferative activity of violaxanthin isolated from bioguided fractionation of Dunaliella tertiolecta extracts.

Authors:  Virginie Pasquet; Perrine Morisset; Said Ihammouine; Amandine Chepied; Lucie Aumailley; Jean-Baptiste Berard; Benoit Serive; Raymond Kaas; Isabelle Lanneluc; Valerie Thiery; Mathieu Lafferriere; Jean-Marie Piot; Thierry Patrice; Jean-Paul Cadoret; Laurent Picot
Journal:  Mar Drugs       Date:  2011-05-11       Impact factor: 6.085

Review 3.  Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.

Authors:  Tsz-Ying Lau; Hiu-Yee Kwan
Journal:  Mar Drugs       Date:  2022-05-30       Impact factor: 6.085

Review 4.  Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health.

Authors:  Juan Peng; Jian-Ping Yuan; Chou-Fei Wu; Jiang-Hai Wang
Journal:  Mar Drugs       Date:  2011-10-10       Impact factor: 6.085

5.  Dietary algae and HIV/AIDS: proof of concept clinical data.

Authors:  J Teas; M R Irhimeh
Journal:  J Appl Phycol       Date:  2011-12-29       Impact factor: 3.215

Review 6.  Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment.

Authors:  Luc J Martin
Journal:  Mar Drugs       Date:  2015-07-31       Impact factor: 5.118

Review 7.  Cancer preventive efficacy of marine carotenoid fucoxanthin: cell cycle arrest and apoptosis.

Authors:  Thamaraiselvan Rengarajan; Permaiyan Rajendran; Natarajan Nandakumar; Maruthaiveeran Periyasamy Balasubramanian; Ikuo Nishigaki
Journal:  Nutrients       Date:  2013-12-06       Impact factor: 5.717

8.  Fucoxanthin Protects Cultured Human Keratinocytes against Oxidative Stress by Blocking Free Radicals and Inhibiting Apoptosis.

Authors:  Jian Zheng; Mei Jing Piao; Young Sam Keum; Hye Sun Kim; Jin Won Hyun
Journal:  Biomol Ther (Seoul)       Date:  2013-07-30       Impact factor: 4.634

9.  Influences of Fucoxanthin on Alveolar Bone Resorption in Induced Periodontitis in Rat Molars.

Authors:  Oguz Kose; Taner Arabaci; Hatice Yemenoglu; Adem Kara; Seckin Ozkanlar; Sevki Kayis; Zeynep Yesil Duymus
Journal:  Mar Drugs       Date:  2016-03-30       Impact factor: 5.118

Review 10.  Antioxidant and Signal-Modulating Effects of Brown Seaweed-Derived Compounds against Oxidative Stress-Associated Pathology.

Authors:  Rahima Begum; Saurav Howlader; A N M Mamun-Or-Rashid; S M Rafiquzzaman; Ghulam Md Ashraf; Ghadeer M Albadrani; Amany A Sayed; Ilaria Peluso; Mohamed M Abdel-Daim; Md Sahab Uddin
Journal:  Oxid Med Cell Longev       Date:  2021-07-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.